Life sciences company focusing on development and delivery of psychedelics and natural-sourced therapies to treat traumatic-brain injuries and other mental conditions Wesana Health Holding Inc. (CSE: WESA) (OTCQB: WSNAF) announced the appointment of Dr. Rachel Yehuda to its scientific advisory board.
Dr. Yehuda is a PhD holder and a professor of psychiatry at the Icahn School of Medicine at Mount Sinai. Additionally, she is also a director of the Center of for Psychedelic Psychotherapy and Trauma Research at Mount Sinai which is currently researching on how MDMA-assisted psychotherapy with compounds such psilocybin can be used to treat trauma.
Dr. Yehuda is also of the Traumatic Stress Studies Division at Icahn Mount Sinai. The division comprises of post-traumatic stress disorder (PTSD) clinical research program.
Following her appointment in Wesana Health, Dr. Yehuda will be mandated to provide strategic guidance and direction to the company’s scientific research efforts related to psychedelic-assisted psychotherapy and traumatic brain injury.
“The research of novel treatment approaches for trauma and other mental health conditions through psychedelics may fundamentally change our understanding of these conditions, as well as the current treatment landscape. For that to happen though, the research must be held to the highest possible standard. As part of Wesana’s Scientific Advisory Board, I look forward to offering my guidance and experience on this front as they explore ways to improve neurological health,” said Dr. Yehuda.